Redx Pharma Appoints New Chairman
News Sep 06, 2014
Frank, 57, brings a wealth of industry knowledge and highly relevant experience of oncology and anti-infectives, two of the areas of early stage drug research that have driven expansion at the company, which operates from bases in Liverpool and Alderley Park, Cheshire.
Dr Peter Jackson, co-founder and director at Redx, said: “We are delighted to welcome Frank to our board. His pharma business experience and clinical insight will make a valuable contribution to our plans for further growth and he is extremely well networked internationally. His skills and instincts are closely aligned to the breadth of our programmes in oncology and anti-infectives, and our early-stage partnering business model.”
Frank began his career as a physician before moving into the Pharma industry. He has considerable public and private company expertise, and his current roles include nonexecutive directorships with Columbia Laboratories (NASDAQ) and Actino Pharma. He is chairman of CardioRentis, Summit PLC and Xceleron and an advisor to Healthcare Royalty Partners.
His big pharma credentials include Zeneca, where he was a senior vice president, and Bayer, where he was executive vice president and head of worldwide product development.
Frank Armstrong commented, “I am delighted to be appointed Chairman of Redx at an exciting time for the company where our technology is increasingly recognized as a source of novel compounds by the Pharma industry. I am looking forward to working with the management team and Board at Redx as we build the company for greater success.”
Nano and Micro Join Forces to Treat OsteoarthritisNews
There is currently no treatment for curing osteoarthritis, which affects 80% of the population over 75 years of age. But researchers who have been studying the problem have come up with a new treatment that delivers previously-identified active principles directly into the joint in the form of nanocrystals inserted into microparticles.READ MORE
Fragile X: Drug Strategy Could Alleviate Behavioral & Cellular DeficienciesNews
Research in mice shows that a pharmacological strategy can alleviate multiple behavioral and cellular deficiencies in a mouse model of fragile X syndrome (FXS), the most common inherited form of intellectual disability and a major single-gene cause of autism spectrum disorders.READ MORE